Delix Therapeutics, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

The US FDA will face some crucial tests for its nascent approach to regulation of psychedelic drug candidates in the coming year, headlined by an 11 August 2024 user fee goal for the first psychedelic

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

In order to bring its psychedelic-based therapy for depression to market, Delix Therapeutics, Inc. has to do three things: show that it spurs the growth of new synapses in the brain; show that it do